January 8, 2019 11:56 AM EST

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China

Amber Tong

A Chinese biotech armed with an arsenal of APIs and finished dosage forms of specialty generic drugs has just raised $80 million (RMB$550 million) to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Ramp­ing up in-house drug de­vel­op­ment, API mak­er Bright­Gene bags $80M round led by Se­quoia Chi­na

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Ramping up in-house drug development, API maker BrightGene bags $80M round led by Sequoia China